| Literature DB >> 30809381 |
Jesus Ruiz1, Monica Gordon1, Esther Villarreal1, Juan Frasquet2, María Ángeles Sánchez3, María Martín1, Álvaro Castellanos3, Paula Ramirez3.
Abstract
Background: The aim of this study is to evaluate the risk factors for colonisation by multidrug resistant (MDR) K. pneumoniae in a critical care unit and the relationship between colonisation and the antibiotic pressure exerted by the antimicrobial treatments received by patients.Entities:
Keywords: Antibiotic; Colonization; Critcal care; K pneumoniae; Multidrug resistance
Mesh:
Substances:
Year: 2019 PMID: 30809381 PMCID: PMC6375121 DOI: 10.1186/s13756-019-0484-8
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Characteristics of patients included in the study
| Total | Patients colonized by | Patients not colonized by | p | |
|---|---|---|---|---|
| Age (SD) | 60.9 (15.2) | 58.1 (14.9) | 61.5 (15.2) | < 0.001 |
| Male (%) | 1097 (63.6) | 203 (65.9) | 895 (63.2) | 0.364 |
| Length of stay (SD) | 9.85 (10.46) | 19.3 (16.1) | 7.8 (7.3) | < 0.001 |
| 1ICU mMortality (%) | 338 (19.6) | 95 (30.8) | 243 (17.1) | < 0.001 |
| APACHE II (median, IQR) | 19 (14–24) | 21 (18–25) | 18 (13–24) | < 0.001 |
| Hematologic disease | 120 (6.9) | 19 (6.2) | 101 (7.1) | 0.531 |
| Solid organ tTransplantation | 73 (4.2) | 18 (5.8) | 55 (3.9) | 0.133 |
| Immunosuppression | 267 (15.5) | 60 (19.4) | 207 (14.6) | 0.035 |
| Diabetes | 351 (12.4) | 65 (21.1) | 268 (20.2) | 0.722 |
| Cirrhosis | 64 (3.7) | 18 (5.8) | 46 (3.2) | 0.028 |
| 2EPOCCOPD | 351 (20.3) | 93 (30.2) | 258 (18.3) | < 0.001 |
| Mechanical vVentilation (%) | 408 (23.7) | 85 (27.6) | 324 (22.8) | 0.077 |
| Renal rReplacement therapy (%) | 142 (8.2) | 21 (6.8) | 121 (8.5) | 0.319 |
| Parenteral nNutrition | 753 (34.1) | 103 (33.4) | 408 (28.8) | 0.109 |
| Origin | 0.179 | |||
| Emergency dDepartment | 793 (46.0) | 126 (40.9) | 667 (47.1) | |
| Hospitalization | 378 (21.9) | 92 (29.9) | 461 (32.5) | |
| Other hHospital | 534 (30.9) | 90 (29.2) | 282 (19.9) | |
| Cause of admission | < 0.001 | |||
| Respiratory infection | 321 (18.6) | 77 (25.0) | 243 (17.1) | |
| Sepsis/Septic sShock | 181 (10.5) | 24 (7.8) | 156 (11.0) | |
| Cardiovascular disease | 567 (32.9) | 60 (19.5) | 507 (35.8) | |
| Other | 976 (56.7) | 147 (47.7) | 511 (36.1) |
1ICU: Intensive care unit; 2COPD: Chronic obstructive pulmonary disease
Fig. 1Percentage of patients colonised in the unit and new colonisations according to the number of weeks of stay in the unit. P-values represent the differences in percentages of patients colonised and new colonisations between each week and the previous one
Results from the univariante analysis
| OR (IC95%) | P | |
|---|---|---|
| Age > 60 years | 0.86 (0.40–1.83) | 0.700 |
| Length of stay > 7 days | 6.52 (4.84–8.52) | < 0.001 |
| APACHE II > 20 | 1.98 (0.89–2.62) | 0.092 |
| Hematologic disease | 0.84 (0.17–3.97) | 0.825 |
| Solid Organ Transplantation | 1.59 (0.31–8.26) | 0.580 |
| Origin | 1.38 (1.21–1.57) | 0.168 |
| Immunosuppression | 1.27 (0.47–3.40) | 0.641 |
| Diabetes | 0.63 (0.26–1.56) | 0.320 |
| Cirrhosis | 1.92 (0.36–10.37) | 0.477 |
| 1COPD | 0.89 (0.82–1.74) | 0.380 |
| Mechanical ventilation | 1.34 (0.61–2.95) | 0.465 |
| Renal replacement therapy | 1.66 (0.91–2.14) | 0.134 |
| Parenteral Nutrition | 2.18 (1.01–4.69) | 0.045 |
| Respiratory infection | 2.05 (0.93–4.53) | 0.074 |
| Sepsis/Septic Shock | 0.39 (0.04–2.69) | 0.306 |
| Antibiotics > 48 h | 5.60 (3.92–7.98) | < 0.001 |
| Carbapenem | 1.33 (0.93–1.89) | 0.108 |
| Quinolones | 1.21 (0.85–1.70) | 0.297 |
| 2IBL | 3.75 (2.83–4.97) | < 0.001 |
| Cephalosporin | 1.87 (1.38–2.53) | < 0.001 |
| Amynoglycosides | 3.78 (2.67–5.37) | < 0.001 |
| Linezolid | 3.02 (1.21–4.17) | < 0.001 |
| 3SDD | 0.45 (0.05–3.64) | 0.454 |
1COPD: Chronic obstructive pulmonary disease; 2BLI: b-lactamase inhibitors; 3SDD: Selective digestive decontamination
Results from the multivariate analysis
| OR (IC95%) | P | |
|---|---|---|
| Length of stay > 7 days | 3.76 (1.89–5.00) | < 0.001 |
| APACHE II > 20 | 1.14 (0.84–1.56) | 0.400 |
| Respiratory infection | 1.75 (1.27–2.42) | 0.002 |
| Origin | 1.23 (0.89–1.63) | 0.327 |
| Renal replacement therapy | 1.23 (0.80–1.90) | 0.136 |
| Parenteral Nutrition | 1.32 (0.96–1.80) | 0.087 |
| Antibiotics > 48 h | 2.86 (1.83–4.48) | < 0.001 |
| 1IBL1BLI | 1.89 (1.68–8.33) | < 0.001 |
| Cephalosporin | 1.85 (1.33–2.69) | 0.214 |
| Aminoglycosides Aminoglucósidos | 2.04 (1.35–2.10) | 0.001 |
| Linezolid | 1.38 (0.96–1.98) | 0.098 |
| Carbapenem | 0.79 (0.53–1.16) | 0.230 |
1BLI: b-lactamases inhibitors
Fig. 2Days until K. pneumoniae colonisation of the patients included based on the use of antimicrobials
Relationship between antibiotic use (Daily Defined Dose) and colonization
| % Colonization during the same month | % Colonization during the next month | |||
|---|---|---|---|---|
| Coefficient | Coefficient | |||
| Carbapenem | 0.720 | 0.220 | 0.380 | 0.043* |
| Quinolones | −0.079 | 0.688 | −0.086 | 0.669 |
| 1BLI | −0.048 | 0.856 | 0.065 | 0.787 |
| Cephalosporin | −0.665 | 0.164 | 0.616 | 0.013* |
| AminoglycosidesAmynoglycosides | 0.392 | 0.472 | 0.833 | 0.226 |
| Linezolid | 0.569 | 0.075 | 0.287 | 0.434 |
| Total | −0.055 | 0.163 | 0.024 | 0.557 |
1IBL1BLI: b-lactamases Inhibitors
*Statistically significant